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Reduction of nephrotic range albuminuria is associated with
markedly improved renal and cardiovascular outcome in
patients with diabetic nephropathy. Aldosterone has been
suggested to play a role in the progression of diabetic
nephropathy. We therefore aimed to evaluate the short-term
effect of aldosterone antagonism with spironolactone on
nephrotic range albuminuria and blood pressure in diabetic
nephropathy. Twenty Caucasian patients with diabetic
nephropathy and nephrotic range albuminuria (42500 mg/
24 h) despite recommended antihypertensive treatment
completed this double-masked, randomized crossover trial.
Patients were treated in random order with spironolactone
25 mg once daily and matched placebo for 2 months, on top
of ongoing antihypertensive treatment, including an
angiotensin-converting enzyme inhibitor or an angiotensin II
receptor blocker in maximally recommended doses. Median
(range) number of antihypertensive drugs was 3 (2–5). After
each treatment period, albuminuria, 24-h ambulatory blood
pressure, and glomerular filtration rate (GFR) were
determined. Spironolactone on top of recommended
renoprotective treatment induced a 32% (95% confidence
interval (CI): 21–42%) reduction in albuminuria from
(geometric mean (95% CI)) 3718 (2910–4749) mg/24 h on
placebo treatment (Po0.001). There was a significant
reduction in 24-h blood pressure of 6 (2–10)/4 (2–6) mm Hg
and day blood pressure of 7 (3–12)/5 (3–7) mm Hg (Po0.01),
whereas night blood pressure remained unchanged.
Spironolactone induced an insignificant reversible reduction
in GFR of 3 ml/min/1.73 m2 from 64 (27) ml/min/1.73 m2. No
patients were excluded due to adverse events. Our results
suggest that spironolactone treatment on top of
recommended renoprotective treatment including maximal
renin–angiotensin system blockade may offer additional
renoprotection in patients with diabetic nephropathy and
nephrotic range albuminuria.
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Diabetic nephropathy has become the single most important
cause of end-stage renal disease (ESRD) in the Western
world.1 Approximately one-third of all diabetic patients
develop diabetic nephropathy. Before the introduction of
aggressive antihypertensive treatment, the clinical course of
diabetic nephropathy was characterized by a continuous
increase in blood pressure and albuminuria, and an inevitable
decline in glomerular filtration rate (GFR) of approximately
10–15 ml/min/year.1 Thus, ESRD and death ensued on
average within 5–7 years after the onset of diabetic
nephropathy.2 The fact that the degree of albuminuria is
closely related to renal and cardiovascular outcome is well
established,3–6 and patients with nephrotic range proteinuria
(proteinuria 43500 mg/24 h;7 corresponding to albuminuria
42500 mg/24 h as reported previously8) indeed carry the
highest risk of ESRD,5 cardiovascular morbidity6 and
mortality, and consequently the shortest survival time.9,10
Previously, the onset of nephrotic range albuminuria was
considered to mark an inexorable progression to ESRD or
death. It has however been demonstrated that remission of
nephrotic range albuminuria is possible, and that it slows the
progression in diabetic nephropathy, reduces the risk of
ESRD, and improves survival in type I and type II diabetic
patients with diabetic nephropathy.9,10
Recently, aldosterone antagonism has been shown to
reduce albuminuria in diabetic and non-diabetic nephro-
pathies.11–14 However, the effect in patients with persistent
nephrotic range albuminuria despite recommended renopro-
tective treatment has not been determined. In the present
study, we evaluated the short-term effect of blocking
aldosterone with spironolactone added to ongoing recom-
mended renoprotective treatment including an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin II
receptor blocker (ARB) and diuretics, on albuminuria and
blood pressure in patients with diabetic nephropathy and
nephrotic range albuminuria.
RESULTS
A total of 20 Caucasian patients were randomized in the
trial; all of whom completed the study and were included
in the statistical analysis. Baseline clinical data and
baseline anti-hypertensive treatment are presented in
Table 1.
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The effects of spironolactone treatment are summarized in
Table 2. During treatment with spironolactone in addition to
conventional antihypertensive treatment, albuminuria was
significantly reduced by 32% (95% confidence interval (CI):
21–42) compared to placebo treatment (Po0.001; Table 2).
The reduction in albuminuria was demonstrated in 17 of the
20 patients (Figure 1). There was a significant reduction in
24-h ambulatory blood pressure (ABP) of 6 (2–10)/4
(2–6) mm Hg and day ABP of 7 (3–12)/5 (3–7) mm Hg
(Po0.01; Table 2), whereas night ABP remained unchanged
during spironolactone treatment.
There was a statistically insignificant trend toward a
decline in GFR of 3 (1 to 6) ml/min/1.73 m2 and an increase
in plasma creatinine of 8 (4 to 20) mmol/l. The fractional
clearance of albumin (yalb) was reduced by 31% (20–40)
(Table 2).
There was a tendency toward an increase in plasma
potassium during spironolactone treatment. Urinary sodium
excretion, K/Na excretion rate, and plasma sodium were
similar in the two treatment periods (Table 2). Plasma
aldosterone levels increased by 80% (25–162) on spirono-
lactone treatment compared to placebo treatment, and there
was an increase in plasma renin activity (PRA) of 81%
(25–162) during spironolactone treatment. There was a trend
toward a decline in hemoglobin during treatment. HbA1c and
cholesterol levels remained unchanged during treatment
(Table 2).
A subanalysis comparing type I and type II diabetic
patients did not reveal any differences in response to
spironolactone treatment in regard to changes in albumin-
uria, 24-h ABP, day ABP, or GFR (P40.2 for all comparisons,
data not shown).
A total of five patients had albuminuria o2.5 g/24 h
during placebo treatment (Figure 1) despite nephrotic range
albuminuria at randomization. When data from these five
patients were excluded from the analysis, there was a
reduction in albuminuria of 32% (95% CI 20–41%,
Po0.001), a reduction in 24-h ABP of 4 (0.3–8, P¼ 0.04)/3
(1–6, P¼ 0.01), and a reduction in day ABP of 6 (1–11,
P¼ 0.01)/4 (2–7, P¼ 0.002). Night ABP remained unchanged
and there was an insignificant reduction in GFR of 3 ml/min/
1.73 m2 (P¼ 0.17), that is, identical results in the remaining
15 patients as compared to n¼ 20.
Using linear regression analysis, we found no association
between changes in albuminuria upon spironolactone
treatment and baseline variables (placebo period). Baseline
albuminuria was not significantly correlated to changes in
albuminuria (R¼ 0.21, P¼ 0.37, that is, there was no order
effect.
Changes in albuminuria were neither correlated to
changes in systolic or diastolic 24-h ABP (Ro0.34,
P40.17) nor to changes in systolic or diastolic day ABP
(Ro0.26, P40.3) in univariate analyses. Furthermore, the
reduction in albuminuria did not correlate significantly with
changes in GFR.
There was no significant correlation between aldosterone
levels at baseline and changes in albuminuria (R¼ 0.33,
P¼ 0.15) or changes in blood pressure (Ro0.3, P40.26).
Neither changes in plasma aldosterone nor in PRA correlated
significantly to changes in albuminuria (R¼ 0.22, P¼ 0.34,
and R¼ 0.13, P¼ 0.59, respectively). However, there was an
inverse correlation between changes in PRA and changes in
24-h and day diastolic ABP (R40.48, Po0.05), and a trend
toward a similar inverse correlation between changes in
plasma aldosterone levels and changes in day diastolic ABP
(R¼ 0.45, P¼ 0.06), that is, the larger the compensatory
increase in hormones, the larger the reduction in diastolic
ABP.
The statistical analysis revealed no evidence of a time or
carryover effect on albuminuria, ABP, GFR, PRA, or plasma
aldosterone.
Throughout the study, all patients received renin–angio-
tensin system (RAS)-blocking treatment in recommended
doses (Table 1); doses remained unchanged during the study.
The median number of antihypertensive drugs in addition to
the study medication was 3 (range 2–5). Compliance as
assessed by tablet count was 99% (85–100), that is, all patients
fulfilled the compliance criteria of 480%. Furthermore,
compliance was assessed by evaluating the changes in plasma
aldosterone and PRA. The three patients not responding to
spironolactone treatment with a decline in albuminuria
Table 1 | Baseline clinical data and baseline antihypertensive
treatment in 20 patients with diabetic nephropathy and
nephrotic range albuminuria
Type I diabetes
(n=9)
Type II diabetes
(n=11)
Age (years) 4578 5279
Gender (male/female) 8/1 9/2
Duration of diabetes (years) 3078 1478
Retinopathy,
none/background/proliferative
0/4/5 2/6/3
Total number of antihypertensive
drug, 2/3/4/5
5/1/3/0 1/5/4/1
Patients receiving
RAS-blocking agent
Enalapril 40/20 mg 3/3 3/0
Trandolapril 4 mg — 1
Losartan 100/150 mg 2/0 3/1
Irbesartan 300 mg — 2
Valsartan 160 mg — 1
Dual blockade of RAS
Lisinopril 20 mg+irbesartan 300 mg 1 —
Patients receiving diuretics,
thiazide/loop diuretic
2/7 2/10a
Patients receiving dihydropyridines 3 9
Patients receiving b-blockers 2 6
Patients receiving moxonidine 1 0
Patients receiving statins 6 11
Patients receiving low-dose aspirin 6 10
RAS, renin–angiotensin system.
Data are expressed as n, mean7s.d.
aOne patient received both a thiazide and a loop diuretic.
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(Figure 1) all had an increase in plasma aldosterone of
30–147% and an increase in PRA of 110–200%.
Safety
No patients were excluded from the study. One patient
complained of transient symptoms of orthostatic hypoten-
sion. Two patients were treated with kayexalate (sodium
polystyrene sulfonate) due to slightly elevated plasma
potassium (5.0–5.5). However, hyperkalemia was present in
both treatment periods in one patient, and only in the
placebo period in the other patient, that is, not specific for
spironolactone treatment.
DISCUSSION
In our double-masked, randomized placebo-controlled cross-
over trial, we found that spironolactone on top of
recommended renoprotective treatment reduced albuminuria
and fractional albumin clearance in patients with diabetic
nephropathy and nephrotic range albuminuria. Twenty-four-
hour ABP was reduced by 6/4 mm Hg. Spironolactone
treatment did not induce a significant reduction in GFR. The
reduction in albuminuria was not significantly associated
with reduction in ABP. Furthermore, the albuminuria-
lowering effect of aldosterone antagonism was independent
of both baseline levels and changes in plasma aldosterone
levels. However, the reduction in diastolic 24-h and day ABP
was inversely associated with changes in PRA, that is, the
larger the compensatory increase in PRA, the larger the
reduction in diastolic ABP. Spironolactone treatment was
generally well tolerated.
The present design of a double-masked, randomized,
crossover study, lasting 2–3 months in each treatment arm
has previously been applied successfully to evaluate new
renoprotective drugs and combinations of drugs.11,14–18
It has recently been shown that aldosterone antagonism
reduces albuminuria with or without concurrent blood
pressure reduction in type I and type II diabetic patients
with micro- or macroalbuminuria.11–14 In the present study,
we extended these observations to patients with diabetic
nephropathy and nephrotic range albuminuria.
Previous studies in diabetic kidney disease have demon-
strated that the maximal antiproteinuric effect occurs within
1–2 weeks after RAS blockade.19,20 Similarly, the predominant
antiproteinuric effect of RAS blockade in IRMA221 and
Table 2 | Effects of adding spironolactone 25 mg o.d. to ongoing recommended antihypertensive treatment in 20 patients with
diabetic nephropathy and nephrotic range albuminuria
Conventional antihypertensive treatment
Mean difference (95% CI) P-value
+Placebo +Spironolactone 25 mg
Albuminuria (mg/24 h)a 3718 (2910–4749) 2510 (1831–3441) 32% (42 to 21) o0.001
Systolic blood pressure (mm Hg)
Office 146 (4) 142 (4) 4 (11 to 4) 0.32
24-hb 143 (3) 137 (3) 6 (10 to 2) 0.004
Day (7–23)b 147 (3) 140 (4) 7 (12 to 3) 0.002
Night (23–7)c 135 (3) 133 (4) 2 (7 to 2) 0.32
Diastolic blood pressure (mm Hg)
Office 76 (2) 73 (2) 3 (6 to 0.4) 0.08
24-hb 81 (2) 77 (2) 4 (6 to 2) 0.001
Day (7–23)b 84 (2) 80 (2) 5 (7 to 3) o0.001
Night (23–7)c 74 (2) 73 (2) 1 (4 to 2) 0.44
GFR (ml/min/1.73 m2) 64 (2) 62 (2) 3 (6 to 1) 0.13
Fractional albumin clearance (yalb) ( 106)a 1.79 (1.25–2.56) 1.24 (0.82 to1.87) 31% (40 to 20) o0.001
Urinary sodium excretion (mmol/24 h) 239 (36) 210 (19) 29 (84 to 26) 0.28
Urinary K/Na ratio 0.43 (0.05) 0.43 (0.04) 0.01 (0.06 to 0.07) 0.78
Bodyweight (kg) 93.8 (5.7) 92.6 (5.6) 1.1 (0.1 to 2.4) 0.07
Plasma renin activity (ng AI/ml/h)a 8.9 (5.8–13.5) 16.1 (9.2–28.1) 81% (25–162) 0.003
Plasma aldosterone (pg/ml)a 38 (25–56) 68 (50–93) 80% (23–163) 0.004
Plasma creatinine (mmol/l) 141 (15) 149 (15) 8 (4 to 20) 0.17
Plasma potassium (mmol/l) 4.1 (0.1) 4.3 (0.1) 0.2 (0.004 to 0.5) 0.054
Plasma sodium (mmol/l) 139 (1) 138 (1) 1 (3 to 1) 0.28
Hemoglobin (mmol/l) 7.6 (0.2) 7.3 (0.2) 0.2 (0.5 to 0.01) 0.057
Hemoglobin A1c (%) 8.2 (0.3) 8.4 (0.3) 0.2 (0.1 to 0.5) 0.20
Plasma cholesterol (mmol/l) 4.7 (0.3) 4.6 (0.2) 0.1 (0.4 to 0.3) 0.74
Plasma LDL cholesterol (mmol/l) 2.3 (0.2) 2.3 (0.2) 0.0 (0.3 to 0.3) 0.88
Plasma HDL cholesterol (mmol/l) 1.5 (0.2) 1.5 (0.1) 0.07 (0.2 to 0.04) 0.20
GFR, glomerular filtration rate; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CI, confidence interval.
Data are expressed as mean (s.e.).
aGeometric mean (95% CI).
bn=18 because of insufficient measurements.
cn=17 because of insufficient measurements.
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RENAAL22 was observed at the first measuring point (3–6
months). A small additional reduction in albuminuria
occurred in both trials, simultaneously with an additional
reduction in blood pressure. The effect on albuminuria of
spironolactone in combination with ACEI or both ACEI and
ARB has recently been reported to be maintained after 12
months treatment,23 further suggesting a potential long-term
beneficial effect. Several long-term studies have shown that
the short-term reduction in albuminuria after initiation of
antihypertensive treatment is a strong predictor of the long-
term renal and cardiovascular outcome, that is, the patients
with the greatest albuminuria reduction have the best long-
term renal and cardiovascular outcome.4–6,8–10,24 A reduction
in albuminuria of 50% has been reported to be associated
with a reduction in the risk of developing ESRD of 45% and
heart failure of 27% in type II diabetic patients with diabetic
nephropathy.5,6 If we extrapolate from these data, the
reduction in albuminuria of 32% observed in our study
would translate into a relative risk reduction of 29% for
progression to ESRD; however, long-term studies are needed
in order to evaluate whether the short-term beneficial effect
on the surrogate end point, albuminuria, is associated with
the suggested reduction in development of ESRD and
cardiovascular events.
There was no carryover effect on the albuminuria-
lowering effect in our study, emphasizing that treatment
effect is not maintained when treatment is interrupted, as
previously shown for other RAS-blocking agents.15,20
All patients received RAS blockade with either ACEI or
ARB. The doses used of the different drugs are regarded as
the maximal recommended for blood pressure reduction.
Valid dose escalation studies using ultra-high doses of ACEIs
and ARBs for renoprotection were not available when our
study was conducted. Recent short-term studies of dual RAS
blockade in type I and type II diabetic patients with
nephropathy have demonstrated additional blood pressure
and albuminuria-lowering effect.17,18 Unfortunately, long-
term studies dealing with safety and efficacy during treatment
with ultra-high doses of ACEIs or ARBs or dual RAS
blockade are lacking in diabetic nephropathy and guidelines
do not recommend this type of therapy, which must be
regarded as experimental. The recommended doses of ACEIs
and ARBs have similar renoprotective effects.16 All patients
received diuretics in doses dependent on clinical effect and
GFR level. Furthermore, additional antihypertensive agents
(calcium channel blockers, b-blockers, or moxonidine) had
been added individually, according to concomitant diseases,
and tolerance to drug effects and side effects. On average,
three blood pressure-lowering agents were prescribed. Con-
sequently, our patients received optimal standard renopro-
tective treatment before entering the study. Furthermore,
most patients received low-dose aspirin and statins (Table 1).
It has previously been reported that a reduction in
albuminuria is associated with a reduction in plasma
cholesterol concentrations.25,26 In our study, there were no
changes in plasma cholesterol levels, probably due to rather
low baseline cholesterol levels induced by treatment with
statins.
In our study, there was a rather large interindividual
variability in response to spironolactone treatment and three
patients did not respond to treatment in terms of reduction
in albuminuria, despite compliance to study medication as
determined by marked increases in plasma aldosterone and
PRA during treatment. It has been suggested that doubling of
the spironolactone dose is effective in patients with essential
hypertension, not responding to spironolactone 25 mg o.d.27
This may also be the case in patients with diabetic
nephropathy. However, one must be extremely cautious
regarding hyperkalemia during treatment with spironolac-
tone in patients with diabetic nephropathy and especially if
higher doses are used. The effect of spironolactone on plasma
potassium levels is dose dependent, as previously reported in
the dose-finding study performed by the RALES investigators
in 212 patients with chronic heart failure (NYHA classes
II–IV) and reduced kidney function;28 80% of the patients
who actually developed hyperkalemia (serum potassium
X5.5 mmol/l) did so within the first 8 weeks of spirono-
lactone treatment. In the present study, we did not observe
hyperkalemia caused by spironolactone. However, our
patients were selected carefully, all having GFR430 ml/
min/1.73 m2 and plasma potassium o4.5 mmol/l at baseline.
Furthermore, all patients were on diuretic treatment (either
loop or thiazide) and all patients received information about
a low-potassium diet. Whether a clinically important
accumulation of potassium occurs during long-term treat-
ment with spironolactone in diabetic patients with nephrotic
range albuminuria is unknown.
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Figure 1 | Individual changes in albuminuria upon spironolactone
treatment in 20 patients with diabetic nephropathy and
nephrotic range albuminuria. Spironolactone was added to
ongoing recommended renoprotective treatment.
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In the present study, effect of aldosterone antagonism did
not depend on baseline levels of aldosterone, that is, even
patients without aldosterone escape, as defined previously,29
benefit from treatment. This is in agreement with findings in
patients with essential hypertension treated with spirono-
lactone.27 Patients with and without primary aldosteronism
responded similarly well on low-dose spironolactone
(12.5–50 mg) with a mean reduction in blood pressure of
25/12 mm Hg after 6 months treatment, although patients
with primary aldosteronism were more likely to have their
dose of spironolactone uptitrated.27
Five of the participating patients had albuminuriao2.5 g/
24 h during placebo treatment despite nephrotic range
albuminuria in the X3 most recent 24-h urine collections
at randomization. There can be a number of reasons for this.
Three of the patients received spironolactone in the first
treatment period, and an individual carryover effect im-
plicating a prolonged effect of spironolactone cannot be
excluded although there was no evidence for an overall
carryover effect. Another explanation could be improved
compliance to ongoing antihypertensive treatment during the
study period, due to increased attention to ones own
condition by the patient. Finally, regression toward the mean
could explain the lower levels of albuminuria; this is however
less likely, as we consistently measured albuminuria on three
consecutive 24-h urine collections to minimize this problem.
In our study, proteinuric type I and type II diabetic
patients were grouped together as previous biopsy studies
have reported that structural changes are similar.1 Further-
more, presence of diabetic retinopathy strongly suggests that
a diabetic glomerulopathy is the cause of albuminuria.30 All
patients except two (where renal biopsy confirmed the
diagnosis) had diabetic retinopathy. Finally, there appears
to be no substantial difference between patients with type I
and type II diabetes with respect to progression and
treatment of diabetic nephropathy.31 We recently published
results from two studies, evaluating the renoprotective effect
of spironolactone in type I11 and type II14 diabetic patients
with diabetic nephropathy and lower grade albuminuria.
These studies showed that type I and type II diabetic patients
responded almost identically to spironolactone therapy with
regard to reduction in albuminuria and blood pressure.11,14
The rationale for blocking aldosterone in patients with
diabetic nephropathy is the findings from recent experi-
mental studies showing that aldosterone induces vascular and
glomerular sclerosis, inflammation, and tubular damage
independently of angiotensin II levels.32–34 Aldosterone
secretion is mainly regulated by angiotensin II levels, but
also by potassium levels and adrenocorticotropic hormone.
Blockade of the RAS with an ACEI or an ARB should
therefore theoretically reduce plasma levels of aldosterone.
An aldosterone escape phenomenon has however been
described during treatment with these agents, that is,
circulating aldosterone levels increase during RAS-blocking
treatment.12,35 We previously reported that aldosterone
escape occurred in 40% of type I diabetic patients with
diabetic nephropathy treated with losartan for 3 years.29
Presence of aldosterone escape was associated with an
enhanced decline in GFR.29
In summary, our short-term study suggests that low-dose
spironolactone in addition to recommended antihypertensive
treatment including ACEIs or ARBs is well tolerated and
induces cardiorenal protection, in terms of reduction in
albuminuria and blood pressure, in patients with diabetic
nephropathy and nephrotic range albuminuria. Special
attention should be paid to plasma potassium levels. Further
studies are needed to evaluate the long-term renoprotective
effect and tolerability of aldosterone antagonism.
MATERIALS AND METHODS
Subjects
From the Steno Diabetes Center, we consecutively enrolled 20
diabetic patients with diabetic nephropathy (17 men and three
women). Based on data in our patient registry, we identified 126
patients who had nephrotic range albuminuria. However, only 42 of
these patients fulfilled all inclusion criteria for the present study and
were invited to participate in the study. Twenty-two of these patients
declined participation and 20 patients agreed to participate in the
study. Data from 12 of these patients have already been included in
previous publications,11,14 but without any detailed analysis of the
impact of spironolactone on nephrotic range albuminuria.
All patients fulfilled the following inclusion criteria: type I or
type II diabetes mellitus, diabetic nephropathy, and hypertension
(4130/80 mm Hg). Furthermore, all patients had persistent
nephrotic range albuminuria (42500 mg/24 h in three consecutive
urine collections) at the time of the screening visit before
randomization, despite antihypertensive treatment, including an
ACEI or ARB in recommended doses. Diabetic nephropathy was
diagnosed clinically if the following criteria were fulfilled: persistent
albuminuria, presence of diabetic retinopathy, and the absence of
any clinical or laboratory evidence of other kidney or renal tract
disease.36 Kidney biopsies verifying the diagnosis of diabetic
glomerulopathy had previously been performed in two patients
not having diabetic retinopathy at study start.
Exclusion criteria at entry were GFR o30 ml/min/1.73 m2,
plasma potassium 44.5 mmol/l, known renal artery stenosis, age
o18 years, pregnancy, breastfeeding, lack of safe contraception in
women, abuse of alcohol or medicine, inability to understand the
patient information, and allergy to ACEI, ARB, or spironolactone.
Prespecified criteria for termination from the study were severe
symptoms of hypotension, systolic blood pressure o100 mm Hg,
increase in plasma creatinine of 435% within the first 2 weeks of
treatment, or plasma potassium 45.5 mmol/l.
Design
We performed a randomized, double-masked, placebo-controlled,
crossover trial consisting of two treatment periods, each lasting 2
months. In random order, patients received spironolactone 25 mg
once daily for 2 months and matching placebo tablets once daily for
2 months. There was no drug washout period between treatment
periods (‘active washout’37). The study medication was given in the
morning and was added to the patients’ ongoing antihypertensive
treatment, including a RAS-blocking agent in recommended doses
(see the Results section). All patients received diuretics in individual
doses before entry into the study to treat and prevent fluid retention
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and hyperkalemia. The type and dose of prior antihypertensive
treatment, including diuretics, remained unchanged throughout the
study.
At the end of each treatment period, the primary end point,
albuminuria, and the secondary end points, 24-h blood pressure and
GFR, were determined. On the day of GFR determination, patients
arrived in a fasting state at 0800, and after 30 min of supine rest the
initial blood samples were drawn and breakfast was served. For
safety reasons, blood pressure, plasma potassium, plasma sodium,
and plasma creatinine were determined 1, 2, and 4 weeks after the
beginning of each treatment period.
Randomization was concealed with computer-generated envel-
opes. The code was not broken until all data were entered into a
database, which was locked for editing.
Drug compliance was assessed by tablet counts, and by
evaluating the expected compensatory increase in plasma aldoster-
one and PRA. Dietary intake of protein and salt was not restricted;
however, all patients were given written and oral information on
how to lower potassium intake in the diet.
The study was performed according to the Declaration of
Helsinki Principles and was approved by the ethical committee of
Copenhagen County. All patients gave their informed consent.
Laboratory procedures
Albuminuria was determined as the geometric mean of three
consecutive 24-h urine collections, completed immediately before
the end of each treatment period (Turbidimetry, Hitachi 912 system;
Roche Diagnostics, Mannheim, Germany) and fractional clearance
of albumin (yAlb) was determined as (urinary albumin excretion)/
(plasma albumin concentration) (GFR).
Urinary excretion of sodium, potassium, creatinine, and urea was
determined as the mean of three consecutive 24-h urine samples
(Hitachi 912 system; Roche Diagnostics).
Blood pressure was measured by a 24-h ABP device (Takeda
TM2421; A&D Medical, Tokyo, Japan). Blood pressure was
measured every 15 min during the day (0700 to 2300) and every
30 min during the night (2300 to 0700). Values were averaged for
each hour before calculating day, night, and 24-h blood pressures.
Office blood pressure was measured using an appropriate cuff with a
sphygmomanometer after at least 10 min rest in the sitting position.
Three readings, 2 min apart and read to the nearest 2 mm Hg, were
recorded and the average value was used for calculation.
GFR was measured after a single intravenous injection of
3.7 MBq 51Cr-EDTA at 0830 by determining the radioactivity in
venous blood samples taken 180, 200, 220, and 240 min after
injection.38,39 The results were standardized for 1.73 m2 body surface
area, using the patient’s surface area at the start of the study. The
mean day-to-day coefficient of variation is 4% in our laboratory.
From venous samples, hemoglobin concentration (Sysmex
SF3000, Sysmex Corporation, Kobe, Japan), and plasma potassium,
sodium, creatinine, and cholesterol concentrations were determined
(Hitachi 912 system; Roche Diagnostics), and HbA1c was measured
by high-performance liquid chromatography (normal range:
4.1–6.4%) (Tosoh automated glycohemoglobin analyser; Tosoh
Bioscience, Minato, Japan). Blood samples for PRA and aldosterone
concentrations were taken after 30 min of supine rest. PRA was
measured by a method based on determining by radioimmunoassay
the amount of angiotensin I generated, as previously described.40
Plasma aldosterone was measured using a commercially available
radioimmunoassay (Coat-a-Count, Diagnostic Products Corpora-
tion, Los Angeles, CA, USA).
Statistical analysis
For power calculation, we previously calculated the s.d. (log scale
0.1771) of the mean difference in urinary albumin excretion rate in
three consecutive 24-h urine samples collected twice within 3
months in 36 patients with diabetic nephropathy. On the basis of
these data, a sample-size calculation showed a necessary minimum
of 16 patients to detect a 25% change in urinary albumin excretion
rate (a¼ 0.05, b¼ 0.80).
Normally distributed variables are expressed as means7s.d.
(Table 1) and means7s.e.m. Changes in variables between visits are
expressed as means with 95% CI. Albuminuria, PRA, plasma
aldosterone, and yAlb clearance were logarithmically transformed
before statistical analysis owing to their skewed distribution and are
given as geometric means (95% CI). Changes in these variables
during treatment with spironolactone as compared to placebo are
expressed in percent. All comparisons of normally or log normally
distributed parameters were performed with a paired Student’s
t-test. Comparison of normally and log normally distributed
parameters between two groups (type I vs type II diabetic patients)
was performed using an independent samples t-test, whereas a
Mann–Whitney test was used for the comparison of urinary sodium
excretion owing to lack of normal distribution. Data were tested for
a time and carryover effect as described by Altman.41
Linear regression analysis was used to analyze for correlations
between the relative change in albuminuria and changes in arterial
blood pressure, GFR, plasma aldosterone levels, and PRA.
Po0.05 was considered significant (two-tailed test). Data were
evaluated using SPSS version 13.0 (SPSS, Chicago, IL, USA).
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